Denali Therapeutics
DNLI
222 hedge funds and large institutions have $1.85B invested in Denali Therapeutics in 2025 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 74 increasing their positions, 81 reducing their positions, and 34 closing their positions.
65% more call options, than puts
Call options by funds: $848K | Put options by funds: $515K
4.71% more ownership
Funds ownership: 88.89% → 93.6% (+4.7%)
3% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 34
0% less funds holding
Funds holding: 223 → 222 (-1)
9% less repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 81
29% less capital invested
Capital invested by funds: $2.61B → $1.85B (-$758M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| 1 |
UBS AM
Chicago,
Illinois
|
+$61M |
| 2 |
Norges Bank
Oslo,
Norway
|
+$38M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$29.9M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$25.1M |
| 5 |
Millennium Management
New York
|
+$20.9M |
Top Sellers
DNLI Hedge Fund Activity: Q1 2025 in Review
222 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Denali Therapeutics (DNLI) for Q1 2025, worth a combined $1.85B — down 29% from $2.61B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new DNLI positions and 34 closed out — a net gain of 1 holder — while 74 added to existing stakes and 81 trimmed.
The largest buyer was UBS AM, adding an estimated $61M. The largest seller was Camber Capital Management, cutting an estimated $19.2M.
- 222 institutional investors held Denali Therapeutics (DNLI) as of Q1 2025, down from 223 in Q4 2024.
- Funds reported $1.85B of Denali Therapeutics stock for Q1 2025, down 29% quarter-over-quarter.
- 35 funds opened new Denali Therapeutics positions in Q1 2025 and 34 closed out, a net change of +1 holder.
- The largest Denali Therapeutics buyer in Q1 2025 was UBS AM, an estimated $61M added.
- The largest Denali Therapeutics seller in Q1 2025 was Camber Capital Management, an estimated $19.2M sold.
Based on aggregated 13F filings for Q1 2025.